Medical Policy Updates

Notification of Policy Revisions Effective August 30, 2011 (Posted May 24, 2011)

Medical Policy	Revision
Monoclonal Antibody Imaging for Prostate Cancer "Notification"	Previously discussed in policy entitled; Monoclonal Antibody Imaging. Monoclonal Antibodies developed into separate policies. Specialty Matched Consultant Advisory Panel review 4/27/2011. "Radioimmunoscintigraphy (Monoclonal Antibody Imaging) using indium-111 capromab pendetide (Prostascint®) is considered investigational." Notification given 5/24/2011. Policy effective 8/30/2011.
KIF6 Genotyping for Predicting Cardiovascular Risk and/or Effectiveness of Statin Therapy "Notification	Evidence Based Guideline converted to Corporate Medical Policy. "KIF6 Genotyping is considered investigational for predicting cardiovascular risk and/or the effectiveness of statin therapy." Reviewed with Senior Medical Director 5/13/2011. Notification given 5/24/11. Policy effective 8/30/11.